The impact of olive oil polyphenol supplementation on metabolic syndrome parameters The OleoMetS study: A randomized, controlled clinical trial.

Olive oil polyphenol supplementation significantly reduced fasting blood glucose and HbA1c compared to placebo in metabolic syndrome patients.

• Mean difference in FBG: -7.06 mg/dL (p < 0.0001)
• Mean difference in HbA1c: -0.29% (p < 0.0001)
• These were the primary endpoints, chosen as key indicators of both short-term and long-term glucose regulation
• The intervention was 10 mg/day polyphenol-rich olive oil extract (80% oleocanthal/oleacein, 18% oleuropein aglycone/ligstroside aglycone) over 12 weeks

OOP supplementation significantly reduced BMI and systolic blood pressure compared to placebo.

• BMI reduction: mean difference -1.15 (p < 0.0001)
• Systolic blood pressure reduction: -7.66 mmHg (p = 0.004)
• No changes to lifestyle were recommended during the intervention period
• Diet and physical activity were assessed at week 6 as a monitoring measure

OOP supplementation significantly improved lipid-related markers, including triglycerides and oxidized LDL.

• Triglycerides reduction: mean difference -8.57 (p = 0.0003)
• Oxidized LDL reduction: mean difference -5.01 (p < 0.0001)
• These were secondary outcomes assessed over the 12-week intervention

OOP supplementation significantly reduced uric acid levels and liver enzyme ALT, and increased estimated glomerular filtration rate.

• Uric acid reduction: mean difference -1.04 (p < 0.0001)
• ALT reduction: mean difference -4.92 (p = 0.0002)
• eGFR increase: mean difference +3.38 (p = 0.0002)
• These were all secondary outcomes in the trial

OOP supplementation significantly reduced fatigue scores compared to placebo.

• Mean difference in fatigue scores: -16.88 (p < 0.0001)
• Fatigue was included as a secondary outcome measure
• The intervention was well-tolerated with no serious adverse events reported

The trial enrolled 102 eligible participants with metabolic syndrome, all of whom completed the 12-week intervention.

• 110 individuals were screened between September 16, 2024, and January 27, 2025
• 8 did not meet inclusion criteria for metabolic syndrome, leaving 102 eligible participants
• Participants were randomly assigned using a computer-generated randomization sequence in a double-blind design
• All 102 randomized participants completed the 12-week intervention and were included in the final analysis
• Repeated measures ANOVA/Linear Mixed Models were used with Bonferroni adjustments for multiple comparisons

The study supplement contained olive oil aldehydic phenols at a dose of 10 mg/day, composed predominantly of oleocanthal and oleacein with smaller amounts of oleuropein aglycone and ligstroside aglycone.

• The supplement composition was 80% oleocanthal/oleacein and 18% oleuropein aglycone/ligstroside aglycone
• Total daily polyphenol dose was 10 mg/day
• Oleocanthal, oleacein, oleuropein aglycone, and ligstroside aglycone are described as 'highly bioactive secoiridoids with unique health-protective properties'
• Preclinical investigations have demonstrated that OOPs possess anti-inflammatory and antioxidant attributes